Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177-DOTATATE and Olaparib in Inoperable GEP-NET
NCT04086485Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2022
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by National Cancer Institute. Started Oct 2022; status: recruiting.
02
Drugs
olaparib
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04086485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086485.